Clinical-stage RNA medicines developer spanning editing, splicing and RNAi
Wave Life Sciences develops oligonucleotide-based RNA therapeutics on its PRISM platform. Its stack pairs genomics tooling (GATK, SAMtools, BLAST, Illumina, PacBio, Nanopore) with in-house Python apps built on Streamlit, Shiny, Flask and FastAPI, which points to a computational biology team building its own tools. Accelerating, senior-weighted hiring targets sequence-based ML, CMC tech transfer and GMP supply, consistent with programs moving toward later-stage clinical manufacturing.
Notable leadership hires: Medical Affairs Lead
Wave Life Sciences is a publicly traded biotechnology company headquartered in Cambridge, Massachusetts, founded in 2012, with 201–500 employees. It designs RNA-targeting medicines across several modalities, including RNA editing, splicing, RNA interference and antisense silencing. Its clinical pipeline covers Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease and obesity, and it also runs preclinical programs. Lab and analytical operations use HPLC, UPLC-MS, LC-MS, LIMS and Phoenix WinNonlin. Commercial and IT functions run on Veeva CRM, Freshservice and CrowdStrike.
Wave uses Python, Streamlit, Shiny, Flask, FastAPI, React and Docker for internal tools. It runs GATK, SAMtools and BLAST on Illumina, PacBio and Nanopore data, along with LIMS, Veeva CRM and Phoenix WinNonlin.
Current work includes sequence-based machine learning, next-generation bioinformatics tools for oligonucleotide therapeutics, drug product formulation studies and external technology transfer for CMC development.
Wave Life Sciences is headquartered in Cambridge, Massachusetts, and currently hires in the United States. The public company has 201–500 employees.
Other companies in the same industry, closest in size
Wave Life Sciences's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.